Cholinesterase inhibitors as Alzheimer's therapeutics
By K. Sharma. Molecular Medicine Reports, 2019
604 citations recorded by the source corpus.
Alzheimer's disease (AD) is one of the most common forms of dementia. AD is a chronic syndrome of the central nervous system that causes a decline in cognitive function and language ability. Cholinergic deficiency is associated with AD, and various cholinesterase inhibitors have been developed for the treatment of AD, including naturally-derived inhibitors, synthetic analogues and hybrids. Currently, the available drugs for AD are predominantly cholinesterase inhibitors. However, the efficacy of these drugs is limited as they may cause adverse side effects and are not able to completely arrest the progression of the disease. Since AD is multifactorial disease, dual and multi-target inhibitors have been developed. The clinical applications and the limitations of the inhibitors used to treat AD are discussed in the present review. Additionally, this review presents the current status and future directions for the development of novel drugs with reduced toxicity and preserved pharmacological activity.
Subfields: Computational Theory and Mathematics, Organic Chemistry, Pharmacology
View Paper: https://www.semanticscholar.org/paper/d15b3bf92f6edd6d46ae16d9307f16add5fa958a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Computational Theory and Mathematics
In Organic Chemistry
In Pharmacology
Citations in the corpus
- Comprehensive Review on Alzheimer’s Disease: Causes and Treatment (2020, background): “Later on, several AChEIs were introduced, such as donepezil (2, Figure 4), rivastigmine (3, Figure 4), and galantamine (4, Figure 4), and are currently in use for the symptomatic treatment of AD [34,97,102,103].”